Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes-Reference-Cited by-同舟云学术

Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes

Published:2017-02-13 Issue:9 Volume:58 Page:2264-2267
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Bohl Stephan R.¹,Dolnik Anna¹,Jensen Thomas²,Lang Katharina M.¹,Hackanson Björn³,Gaidzik Verena I.¹,Paschka Peter¹,Knudsen Steen²,Döhner Konstanze¹,Döhner Hartmut¹,Claus Rainer³,Lübbert Michael³,Bullinger Lars¹

Affiliation:

1. Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;

2. Medical Prognosis Institute (MPI), Hørsholm, Denmark;

3. Department of Internal Medicine I, University of Freiburg Faculty of Medicine, Freiburg, Germany

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1287360

Reference14 articles.

1. Acute Myeloid Leukemia

2. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

3. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML

4. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia

5. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia;Annals of Hematology;2023-09-13

2. A novel 4‐mRNA signature predicts the overall survival in acute myeloid leukemia;American Journal of Hematology;2021-08-14

3. Epigenetic modulators combination with chemotherapy in breast cancer cells;Cell Biochemistry and Function;2021-02-20

4. Epigenetics and Epi-miRNAs: Potential markers/therapeutics in leukemia;Biomedicine & Pharmacotherapy;2018-10

5. Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia;Expert Review of Hematology;2018-03-27